Organization (Industry)
BLUEPRINT MEDICINES CORPORATION
ClinicalTrials.gov lists BLUEPRINT MEDICINES CORPORATION as lead sponsor of 32 trials. It has 66 active development programs and 10 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers BLUEPRINT MEDICINES CORPORATION: 32 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (34)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Mastocytosis | 12 |
| Mastocytosis, Systemic | 11 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Gastrointestinal Stromal Tumors | 7 |
| Lung Neoplasms | 7 |
Showing 5 of 34 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 4 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 5 |
| 2021 | 5 |
| 2020 | 3 |
| 2019 | 4 |
| 2018 | 2 |
| 2016 | 1 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (66)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Elenestinib | Mastocytosis, Systemic | Phase 2/3 | 1 |
| Elenestinib | Mastocytosis | Phase 2/3 | 1 |
| BLU-808 | Chronic Urticaria | Phase 2 | 1 |
| BLU-808 | Chronic Inducible Urticaria | Phase 2 | 1 |
| BLU-808 | Cold Urticaria | Phase 2 | 1 |
Showing 5 of 66 active programs.
Approved assets (10)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Avapritinib | 12 |
| Regorafenib | 1 |
| MIDAZOLAM | 3 |
| CARBOPLATIN | 3 |
| PEMETREXED | 2 |
Showing 5 of 10 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=20) | 37% on time (n=19) |
Journals published in (13)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Blood advances | 2 |
| Nature medicine | 2 |
| The oncologist | 2 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 1 |
| BMC cancer | 1 |
Showing 5 of 13 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 61 | 20 | 2025-10-21 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Organization relationships (9)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Analysis Group (United States) | Co sponsors trial with | 2 |
| CStone Pharmaceuticals (China) | Co sponsors trial with | 2 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 1 |
| LUNGevity Foundation | Co sponsors trial with | 1 |
| G1 Therapeutics (United States) | Co sponsors trial with | 1 |
Showing 5 of 9 relationships.
Latest dated events (99)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-21 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 99 events.
Biomarker capability evidence (247)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ARC | Trial sponsor | Named in trial inclusion criteria |
| ATP12A | Trial sponsor | Named in trial inclusion criteria |
| ATP4A | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 247 evidence rows.
On Scientist.com
BLUEPRINT MEDICINES CORPORATION is listed as a research supplier in the Scientist.com network.
Service areas
Blueprint Medicines has developed a proprietary platform that combines genomics expertise with a novel library of kinase inhibitors to enable the rapid development of potent, highly selective compounds to address clear driver genomic targets. The library was built de novo in an iterative manner and annotated against the entire kinome; it is a proprietary resource of potent and selective tool compounds for ~200 kinases, providing high quality differentiated building blocks for medicinal chemistry programs accelerating the identification of multiple lead series for targets of interest. Our...
Show the full description
Blueprint Medicines has developed a proprietary platform that combines genomics expertise with a novel library of kinase inhibitors to enable the rapid development of potent, highly selective compounds to address clear driver genomic targets.
The library was built de novo in an iterative manner and annotated against the entire kinome; it is a proprietary resource of potent and selective tool compounds for ~200 kinases, providing high quality differentiated building blocks for medicinal chemistry programs accelerating the identification of multiple lead series for targets of interest.
Our genomics expertise enables Blueprint to identify drug targets by sequencing unexplored cancers and mining public data with new genome analysis algorithms.
Blueprint’s ability to discover and develop potent and selective kinase inhibitors against drivers of specific cancers is efficient and reproducible, and we expect to bring two or three programs to the clinic by the end of 2015.
- Website
- www.blueprintmedicines.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Blueprint Medicines on Scientist.com
For prices, more details, or to contact Blueprint Medicines, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.